NuEyes has received approval from the US Food and Drug Administration (FDA) for its new augmented reality loupes, NuLoupes.

NuLoupes is claimed to be the first pair of smart glasses to receive FDA clearance, featuring live 3D stereoscopic imaging.

The patent-pending device integrates modern stereoscopic technology with an advanced design, providing dentistry and medicine practitioners with a better level of precision and live 3D visualisation.

By switching from traditional fixed magnification to NuLoupes' high-resolution variable digital magnification, surgeons and dentists will get increased versatility and a broader field of view.

NuLoupes utilises the company’s camera system for delivering live 3D stereoscopic imaging with near-zero latency.

The camera system provides sub-millimetre accurate depth perception to help physicians understand the viewed environment.

This technology is crucial for providing a natural viewing experience while magnifying detailed work in front of users.

NuEyes plans to provide a limited quantity of NuLoupes developer kits for clinicians, software developers working on medical applications, or individuals seeking early access to NuLoupes before its official market release.

The kit includes a complete SDK, providing exclusive access to the NuLoupes 3D stereoscopic camera sensors, IMU, IR sensor, Android operating system, and Unity plug-ins.

They are expected to be shipped in the first quarter of next year.

NuEyes founder and CEO Mark Greget said: “We are thrilled to announce the FDA approval of NuLoupes, a testament to our commitment to innovation and excellence in the medical technology field.

“NuLoupes represents a huge leap forward in visualisation technology, and we are confident that they will revolutionise the way medical professionals approach their work.”

NuEyes, a smart glasses technology company, is focused on assisting people with eye conditions such as glaucoma, macular degeneration and retinitis pigmentosa.